IL-10 has been considered for conditions characterized by excessive inflammation, showing dual anti-fibrotic and anti-inflammatory effects in pulmonary fibrosis while alleviating viral-induced acute lung injury/acute respiratory distress syndrome (ARDS), positioning it as a potential coronavirus disease 2019 (COVID-19) and other therapeutic candidate [32]. Here, IL10 is linked to acute lung injury.